about
Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies.Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings.Heparin-induced thrombocytopenia--therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes.Direct visualization and identification of biofunctionalized nanoparticles using a magnetic atomic force microscope.Preparation and characterization of magnetizable aerosols.CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects.An oral-controlled release drug delivery system for liquid and semisolid drug formulations.A biorelevant dissolution stress test device - background and experiences.In vivo imaging of drug delivery systems in the gastrointestinal tract.In-vitro dissolution methods for controlled release parenterals and their applicability to drug-eluting stent testing.In vitro dissolution testing of drug-eluting stents.Advances in coronary stent technology--active drug-loaded stent surfaces for prevention of restenosis and improvement of biocompatibility.Simulating the postprandial stomach: biorelevant test methods for the estimation of intragastric drug dissolution.In vitro simulation of realistic gastric pressure profiles.Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers.Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters.Concentration of the macrolide antibiotic tulathromycin in broncho-alveolar cells is influenced by comedication of rifampicin in foals.An automated system for monitoring and regulating the pH of bicarbonate buffers.Development of hydrophobized alginate hydrogels for the vessel-simulating flow-through cell and their usage for biorelevant drug-eluting stent testing.Effect of Coadministered Water on the In Vivo Performance of Oral Formulations Containing N-Acetylcysteine: An In Vitro Approach Using the Dynamic Open Flow-Through Test Apparatus.Effects of non-ionic surfactants on in vitro triglyceride digestion and their susceptibility to digestion by pancreatic enzymes.Magnetic marker monitoring of disintegrating capsules.Mechanistic modeling of a magnetic marker monitoring study linking gastrointestinal tablet transit, in vivo drug release, and pharmacokinetics.Assessing gastrointestinal motility and disintegration profiles of magnetic tablets by a novel magnetic imaging device and gamma scintigraphy.Magnesium used in bioabsorbable stents controls smooth muscle cell proliferation and stimulates endothelial cells in vitro.The role of individual gastric emptying of pellets in the prediction of diclofenac in vivo dissolution.Investigation of gastrointestinal transport by magnetic marker localization.Variability of intestinal expression of P-glycoprotein in healthy volunteers as described by absorption of talinolol from four bioequivalent tablets.Examination of drug release and distribution from drug-eluting stents with a vessel-simulating flow-through cell.Magnetic marker monitoring: high resolution real-time tracking of oral solid dosage forms in the gastrointestinal tract.Comparison of dissolution profiles obtained from nifedipine extended release once a day products using different dissolution test apparatuses.Irregular absorption profiles observed from diclofenac extended release tablets can be predicted using a dissolution test apparatus that mimics in vivo physical stresses.The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen.Changes in recovery due to drug product matrix ageing as a source of mass imbalances.Bioavailability of amoxicillin and clavulanic acid from extended release tablets depends on intragastric tablet deposition and gastric emptying.Development of a vessel-simulating flow-through cell method for the in vitro evaluation of release and distribution from drug-eluting stents.Impact of the intragastric location of extended release tablets on food interactions.Differential interaction of magnetic nanoparticles with tumor cells and peripheral blood cells.Development of oral taste masked diclofenac formulations using a taste sensing system.Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetim
P50
Q33372089-617B407A-FECE-4A13-98B5-2D895E9BC84DQ33378593-5DE264DB-4E34-4C94-A8A4-13E5B6F81191Q33381906-3F5CE1DF-0FCB-4D68-B04B-D0BF3E92B4F2Q33983789-0C4B5C6D-D741-4F59-8A7D-9871CBB7FF85Q34151066-7F318C1C-0755-4155-A15D-06DB695D9E0CQ34303365-C60DE929-106A-45A8-974E-FDADD8225CD2Q35577205-AB023221-BB99-4766-87C5-F280FA01A782Q37803213-E9F2718B-99AE-406F-8B19-19BF8DE586E1Q37912513-95B8C6B7-1B08-44F2-B374-9BA4146EA3EFQ38017707-E9601FB8-C178-4D2E-B71B-1E59BA900DCAQ38054826-B9924276-1DE4-4258-86DE-C64C907CB9B7Q38054828-6B2D67A3-B257-4AF5-A0D4-0735634A52CDQ38105121-2230A63B-8B18-468A-84C4-29A17E2A429BQ38695553-6795F2F6-7CB9-4C05-9048-CFB7F01399C6Q39582716-44B0D908-24D5-4D6E-8CCE-76B880F2BD23Q39712719-A31A3A0C-F378-4111-9786-30CF38FF3EDAQ39762984-26DF1BE7-DB51-4FB7-B010-6D1D8985EFECQ41124271-95B488EF-9DEB-4CDD-87C2-3D7C66C4BB4FQ41879121-887C9EEC-5BF4-4902-8E0F-6A5169FDAC85Q42698746-613056BB-201A-40AE-841A-4227E816FAABQ42969319-B821E45E-074B-4CE9-9821-1A65B3746976Q43641446-5E7D2FE4-2089-4302-B7F0-B2298591138DQ43726337-87D96DCB-26B3-479E-AF0E-1AD85E4627B7Q43783562-F1A159B0-A073-4B1C-A63D-B76B8D0100C3Q43994933-B7E4597A-52B1-4CAE-9BDD-3ED5C90F38DFQ44023496-9544E559-CE4B-4428-BFB1-DC794B96F771Q44237977-D9C8E16D-4A14-47CD-AC0A-48664C094D03Q44315613-ACE01A34-B858-4C6B-9364-87E9A0D049D7Q44480165-040CFFBB-B702-46FD-81B9-A3AF414D1605Q45924844-25CC8383-9210-4FF4-A745-A2CB02BEEC93Q45932615-9AE76315-7B4C-4BB6-92A0-E0FE91B5C69EQ46145391-C99CE34D-A458-4CDB-9CCF-9FD304849535Q46500452-2D9A235B-5E4A-4EF8-9784-13567CC793C0Q46510595-0BE724E0-91AA-4D69-B816-DB3E15F02F16Q46517057-C593D8C5-D5DE-4A99-92DB-CB3F3EB79BC6Q46533865-27857490-D07C-447B-8BC3-30B98A4EE086Q46742313-25FF0388-3EC9-4657-9AFE-8F53D56BE410Q46908343-716790F5-F99D-4EFC-93B0-D09A9D0B76BCQ46944414-C3CFFB30-F3E9-42A7-92D7-AED7070BDE95Q46972806-6575938B-DD5B-4B50-9A77-522CC86FE8E8
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Werner Weitschies
@ast
Werner Weitschies
@en
Werner Weitschies
@es
Werner Weitschies
@nl
Werner Weitschies
@sl
type
label
Werner Weitschies
@ast
Werner Weitschies
@en
Werner Weitschies
@es
Werner Weitschies
@nl
Werner Weitschies
@sl
prefLabel
Werner Weitschies
@ast
Werner Weitschies
@en
Werner Weitschies
@es
Werner Weitschies
@nl
Werner Weitschies
@sl
P106
P21
P31
P496
0000-0003-3492-7747